

**Table S1.** Treatment-Emergent Adverse Events by Grade in  $\geq 15\%$  of Patients Treated With Continuous Dosing of OKI-179

System Organ Class Preferred Term, N (%)	200 mg (N=6)				300 mg (N=2)				All Continuous Patients (N=8)				All grades
	G1	G2	G3	G4	G1	G2	G3	G4	G1	G2	G3	G4	
Constipation	2 (33)	3 (50)	0	0	1 (50)	0	0	0	3 (38)	3 (38)	0	0	6 (75)
Nausea	2 (33)	2 (33)	0	0	2 (100)	0	0	0	4 (50)	2 (25)	0	0	6 (75)
Fatigue	1 (17)	2 (33)	0	0	0	0	1 (50)	0	1 (13)	2 (25)	1 (13)	0	4 (50)
Platelet count decreased	1 (17)	1 (17)	0	0	0	0	0	2 (100)	1 (13)	1 (13)	0	2 (25)	4 (50)
Diarrhea	2 (33)	0	0	0	1 (50)	0	0	0	3 (38)	0	0	0	3 (38)
Headache	2 (33)	0	0	0	1 (50)	0	0	0	3 (38)	0	0	0	3 (38)
Decreased appetite	1 (17)	0	0	0	0	0	1 (50)	0	1 (13)	0	1 (13)	0	2 (25)
Anemia	0	1 (17)	0	0	0	1 (50)	0	0	0	2 (25)	0	0	2 (25)
Abdominal pain	1 (17)	1 (17)	0	0	0	0	0	0	1 (13)	1 (13)	0	0	2 (25)
Dyspepsia	1 (17)	1 (17)	0	0	0	0	0	0	1 (13)	1 (13)	0	0	2 (25)
ECG QT prolonged	1 (17)	1 (17)	0	0	0	0	0	0	1 (13)	1 (13)	0	0	2 (25)
Pain	1 (17)	1 (17)	0	0	0	0	0	0	1 (13)	1 (13)	0	0	2 (25)

Graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5. Abbreviations: Gr, Grade; N, Number. There were no Grade 5 TEAEs in patients treated with continuous dosing.

**Table S2.** Treatment-Emergent Adverse Events by Grade in  $\geq 15\%$  of Patients Treated With Intermittent Dosing of OKI-179 of 5 Days on / 2 Days Off (5:2)

Adverse Event <i>N</i> (%)	300 mg ( <i>N</i> =6)			
	G1	G2	G3	All grades
Nausea	4 (67)	0	1 (17)	5 (83)
Fatigue	1 (17)	3 (50)	0	4 (67)
Platelet count decreased	4 (67)	0	0	4 (67)
Vomiting	2 (33)	1 (17)	0	3 (50)
Decreased appetite	0	1 (17)	1 (17)	2 (33)
Anemia	1 (17)	0	1 (17)	2 (33)
Back pain	1 (17)	0	1 (17)	2 (33)
ECG QT prolonged	2 (33)	0	0	2 (33)
Bile duct stenosis	0	0	1 (17)	1 (17)
Enterococcal bacteremia	0	0	1 (17)	1 (17)
Pneumothorax	0	0	1 (17)	1 (17)
Abdominal pain	0	1 (17)	0	1 (17)
Dysphagia	0	1 (17)	0	1 (17)
Esophagoscopy	0	1 (17)	0	1 (17)
Oropharyngeal pain	0	1 (17)	0	1 (17)
Pain in extremity	0	1 (17)	0	1 (17)
Pneumonitis	0	1 (17)	0	1 (17)
Aspartate aminotransferase increased	1 (17)	0	0	1 (17)
Blood alkaline phosphatase increased	1 (17)	0	0	1 (17)
Dehydration	1 (17)	0	0	1 (17)
Eye pain	1 (17)	0	0	1 (17)
Gastritis	1 (17)	0	0	1 (17)
Hypomagnesaemia	1 (17)	0	0	1 (17)
Myalgia	1 (17)	0	0	1 (17)
Neutrophil count decreased	1 (17)	0	0	1 (17)
Esophagitis	1 (17)	0	0	1 (17)
Paresthesia	1 (17)	0	0	1 (17)

Graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5. Abbreviations: Gr, Grade; *N*, Number. There were no Grade 4 or Grade 5 TEAEs in patients treated with the 5:2 schedule.

**Table S3.** Summary of Key PK Parameters for the 300-mg 5:2 Regimen Cohort

Analyte	Cycle 1 Visit	C <sub>max</sub> (ng/mL)	T <sub>max</sub> (hr)	AUC <sub>last</sub> (hr*ng/mL)	t <sub>1/2</sub> (hr)	MR <sub>AUC</sub>
OKI-179	Day 1	142 (31.2%)	0.875 (0.517 - 2.00)	253 (101%)	1.75 (0.672 - 2.83)	NA
	Day 15	215 (77.1%)	0.934 (0.550 - 1.93)	374 (126%)	1.74 (1.09 - 2.40)	NA
OKI-006 (Free)	Day 1	1770 (37.3%)	0.692 (0.500 - 1.05)	2790 (61.6%)	NA	13.3 (59.7%)
	Day 15	2220 (38.9%)	0.934 (0.500 - 1.93)	3180 (60.3%)	3.43 (0.994 - 6.64)	10.3 (52.4%)
OKI-006 (Total)	Day 1	1990 (36.2%)	0.942 (0.533 - 1.90)	6040 (60.6%)	6.70 (6.14 - 7.07)	28.8 (65.2%)
	Day 15	2420 (33.4%)	0.934 (0.500 - 1.93)	6420 (44.2%)	6.53 (6.30 - 9.68)	20.7 (76.0%)

Values are geometric mean (%CV) for C<sub>max</sub>, AUC<sub>last</sub> and MR<sub>AUC</sub> for N=6 patients in the 300-mg 5:2 regimen cohort. Values are median (min-max) for T<sub>max</sub> and terminal t<sub>1/2</sub>. NA=not applicable. MR<sub>AUC</sub> is the OKI-006 to OKI-179 metabolite ratio based on AUC<sub>last</sub>.

**Table S4.** Mean Acetylation Fold Change from Baseline at 2 Hours Post-dose

Dose (mg)	H3K9			H3K27			Total Lysine		
	CD4	CD8	T-cell	CD4	CD8	T-cell	CD4	CD8	T-cell
30	1.4 (NA)	1.5 (NA)	1.4 (NA)	4.8 (NA)	5.2 (NA)	7.4 (NA)	1.6 (NA)	1.2 (NA)	1.6 (NA)
60	1.6 (0.6)	1.8 (0.6)	2.0 (0.8)	6.0 (3.4)	3.7 (1.9)	4.3 (4.3)	1.4 (NA)	1.2 (NA)	1.3 (NA)
90	1.4 (NA)	2.4 (NA)	2.2 (NA)	2.1 (NA)	4.1 (NA)	4.2 (NA)	0.8 (NA)	1.8 (NA)	1.6 (NA)
120	2.5 (NA)	2.3 (NA)	2.5 (NA)	10.2 (NA)	10.1 (NA)	9.3 (NA)	3.4 (NA)	4.0 (NA)	3.4 (NA)
180	3.3 (NA)	2.6 (NA)	3.1 (NA)	8.8 (NA)	6.2 (NA)	8.0 (NA)	3.0 (NA)	2.2 (NA)	2.7 (NA)
200	2.2 (1.7)	2.3 (1.8)	2.4 (1.8)	3.7 (2.5)	4.0 (2.0)	4.3 (2.5)	2.1 (1.3)	1.9 (1.3)	2.3 (1.4)
210	3.6 (NA)	3.7 (NA)	3.8 (NA)	10.6 (NA)	10.6 (NA)	10.9 (NA)	4.0 (NA)	3.5 (NA)	3.7 (NA)
270	2.5 (0.7)	2.4 (0.5)	2.5 (0.6)	8.0 (2.9)	6.6 (1.8)	6.8 (2.3)	2.9 (0.7)	2.6 (0.4)	2.8 (0.5)
300	1.6 (1.2)	1.4 (0.7)	1.5 (0.8)	6.2 (4.3)	5.4 (2.9)	5.9 (3.3)	2.7 (2.2)	2.5 (1.7)	2.7 (1.6)
350	3.2 (0.1)	1.0 (0.1)	2.9 (0.1)	10.8 (0.9)	1.8 (0.3)	9.6 (1.0)	4.0 (0.1)	2.0 (NA)	3.9 (0.1)
450	4.2 (2.9)	4.5 (2.2)	3.3 (1.9)	9.7 (5.2)	8.8 (4.1)	8.5 (3.5)	3.2 (2.3)	2.6 (1.5)	3.0 (2.1)

Values are mean with standard deviation. NA=not applicable due to limited number of values.